Cáncer de próstata localizado de bajo riesgo.Tratamiento de braquiterapia. Toxicidad y calidad de vida

  1. Rocío Martínez Gutiérrez
Revista:
NPunto

ISSN: 2603-9680,  2605-0110

Año de publicación: 2024

Volumen: 7

Número: 71

Páginas: 51-75

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: NPunto

Resumen

Prostate cancer (PCa) is the second leading cause of cancer in men in the United States and in the European Union. Low-dose-rate brachytherapy (LDR-BT) represents a consolidated treatment option in the management of low risk and intermediate risk localized PCa. However, due to the higher sensitivity to fraction dose of PCa cells, High-dose-rate brachytherapy (HDR-BT) has emerged as a treatment option owing to its highly conformal dose distribution within the prostate and an abrupt dose fall-off outside, saving organs at risk. To realize the potential acute and chronic side effects as well as their impact on health-related quality of life (QoL), are considered important endpoints in the choice of a treatment modality. Despite this, the use of prospective validated questionnaires that assess long-term toxicity of LDR-BT and HDR-BT are rarely used. QoL results are scarce in literature. The aim of this review is to evaluate the evidence of LDR-BT and HDR-BT in the treatment of localized PCa as well as its potential acute and chronic toxicities and QoL impact.

Referencias bibliográficas

  • Amin MB, Edge SB, et al. AJCC cancer staging manual. 8ª ed. Springer Cham; 2017.
  • Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, et al. Prostate Cancer – Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. Ca Cancer J Clin. 2017;00(00):1-8.
  • Carlsson SV, Vickers AJ. Screening for Prostate Cancer. Med Clin North A,m. 2021;104(6):1051-62.
  • Catalona WJ, Richie JP, Ahmann FR, Hudson MLA, Scardino PT, Flanigan RV, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol. 2017;197(2):S200-7.
  • Cooperberg MR, Lin DW. Active Surveillance for Prostate Cancer: 1 2020 Vision. Eur Urol 2020;77(6):687-8.
  • Costello AJ. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nat Rev Urol. 2020;17(3):177-188
  • de Crevoisier R, Supiot S, et al. External radiotherapy for prostatic cancers. Cancer Radiother. 2022;26:329-43.
  • Halperin E.C. Perez and Brady’s Principles and Practice of Radiation Oncology. Lippincott Williams and Wilkins. 7th Ed;2017.
  • Hansen EK, Roach III M. Handbook of Evidence-Based Radiation Oncology. Springer Cham. 3th Ed;2018.
  • Lardas M, Liew M, et al. Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review. Eur Urol 2017;72(6):869-885.
  • Las cifras del cáncer en España, SEOM, Feb 2022. Disponible en: https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf
  • O’Connor L, et al. Use of multiparametris magnetic resonance imaging (mpMRI) in localized prostate cancer. Expert Rev Med Devices. 2020;17(5):435-42.
  • Peters B, Van Limbergen E, Pötter R, et al. The GEC ESTRO Handbook of Brachytherapy. 2nd Ed 2017
  • Pilarski R. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. Am Soc Clin Oncol Educ Book. 2019;39:79-86.
  • Prostate Imaging Reporting and Data System (PI-RADS). American College of Radiology (ACR). Disponible en: http://www.acr.org [última consulta: Septiembre 2022].
  • Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ. Prostate specific antigen as tumor marker in prostate cancer: biochemical and clinical aspects. Advances in Cancer Biomarkers (editor Scatena R). Springer Netherlands. 2015. Part II. 93-114. (Vol 867 of the series Advances in experimental Medicine and Biology).
  • Schaeffer E, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134-43. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf [última consulta: Septiembre 2022].
  • Sebesta EM, Anderson CB. The surgical management of Prostate cancer. Semin Oncol. 2017;44(5):347-357.
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33.
  • Sung H, et al. Global Cancer Statics: GLOBOCAN Estimates of incidence and mortality wordwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
  • Vietri MT, et al. Hereditary Prostate Cancer: Genes related, target therapy and prevention. Int J Mol Sci. 2021;22(7):3753.
  • Wilt TJ, et al. Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review. J Urol 2021;205(4):967-76.
  • World Health Organization. Constitution. En: WHO. Disponible en: Basic Document Geneve WHO 1948.
Fuente de los datos: Dialnet